Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.55 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.55 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30813009 | 1.00 | CYP3A4 (0.58) | CYP3A4LTB4RLTB4R2PARP3DRD2 | |
| SCHEMBL6093233 | 1.00 | CYP3A4 (0.58) | CYP3A4LTB4RLTB4R2PARP3DRD2 | |
| SCHEMBL2070162 | 1.00 | CYP3A4 (0.58) | CYP3A4LTB4RLTB4R2PARP3DRD2 | |
| SCHEMBL6093238 | 1.00 | CYP3A4 (0.58) | CYP3A4LTB4RLTB4R2PARP3DRD2 | |
| SCHEMBL14956962 | 1.00 | CYP3A4 (0.58) | CYP3A4LTB4RLTB4R2PARP3DRD2 | |
| SCHEMBL13268060 | 0.87 | CYP3A4 (0.56) | CYP3A4LTB4RLTB4R2DRD2DRD3 | |
| SCHEMBL17985005 | 0.87 | CYP3A4 (0.60) | CYP3A4LTB4RLTB4R2CYP19A1LMNA | |
| SCHEMBL2069633 | 0.82 | CYP3A4 (0.50) | CYP3A4LTB4RLTB4R2MAOAMAOB | |
| SCHEMBL2069344 | 0.82 | CYP3A4 (0.50) | CYP3A4LTB4RLTB4R2MAOAMAOB | |
| SCHEMBL14198745 | 0.82 | CYP3A4 (0.50) | CYP3A4LTB4RLTB4R2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103641808-B | The enantioselective hydrogenation method of chromene | GIRINDUS AMERICA INC. (US) | 2016-04-20 | — | — | CN | claimed |
| CN-103755675-B | The enantioselective hydrogenation method of chromene | GIRINDUS AMERICA INC. (US) | 2015-11-18 | — | — | CN | claimed |
| EP-1919887-B1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA INC (US) | 2015-02-18 | — | — | EP | claimed |
| US-8765420-B2 | Method for preparing pterocarpan | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-07-01 | — | — | US | claimed |
| CN-101535286-B | Process for the enantioselective hydrogenation of chromenes | GIRINDUS AMERICA INC | 2014-05-07 | — | — | CN | claimed |
| US-8716497-B2 | Method for enantioselective hydrogenation of chromenes | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-05-06 | — | — | US | claimed |
| CN-103755675-A | Method for enantioselective hydrogenation of chromenes | GIRINDUS AMERICA INC | 2014-04-30 | — | — | CN | claimed |
| CN-103641808-A | Method for enantioselective hydrogenation of chromenes | GIRINDUS AMERICA INC | 2014-03-19 | — | — | CN | claimed |
| US-20130130332-A1 | NOVEL METHOD FOR PREPARING PTEROCARPAN | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-05-23 | — | — | US | claimed |
| US-20130116450-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA, INC. (US) | 2013-05-09 | — | — | US | claimed |
| JP-2007511542-A | — | — | 2007-05-10 | — | — | JP | claimed |
| WO-2007016423-A2 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA INC. (US) | 2007-02-08 | — | — | WO | claimed |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | AUSIO PHARMACEUTICALS, LLC | 2007-02-01 | — | — | US | claimed |
| CN-1902213-A | Isoflavonoid prodrugs, compositions thereof and therapeutic methods involving same | NOVOGEN RES PTY LTD (AU) | 2007-01-24 | — | — | CN | claimed |
| CN-1902671-A | English phonetic symbol system | KUOJUI SU (US) | 2007-01-24 | — | — | CN | claimed |
| WO-2006108212-A1 | ANTI-INFLAMMATORY MODALITIES | NOVOGEN RESEARCH PTY LTD (AU) | 2006-10-19 | — | — | WO | claimed |
| EP-1685140-A1 | ISOFLAVONOID PRODRUGS, COMPOSITIONS THEREOF AND THERAPEUTIC METHODS INVOLVING SAME | Novogen Research Pty Ltd (AU) | 2006-08-02 | — | — | EP | claimed |
| WO-2005103025-A1 | ISOFLAVENE SYNTHETIC METHOD AND CATALYST | NOVOGEN RESEARCH PTY LTD (AU) | 2005-11-03 | — | — | WO | claimed |
| WO-2005049627-A1 | ISOFLAVONOID PRODRUGS, COMPOSITIONS THEREOF AND THERAPEUTIC METHODS INVOLVING SAME | NOVOGEN RESEARCH PTY LTD (AU) | 2005-06-02 | — | — | WO | claimed |
| CN-1340048-A | Production of isoflavone derivatives | NOVOGEN RES PTY LTD (AU) | 2002-03-13 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116450-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | HRH3, HRH2, CHD8 | CYP3A4 487/4885LTB4R 3119/4885LTB4R2 2355/4885 |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | HRH3, HRH2, CHD8 | CYP3A4 487/4885LTB4R 3119/4885LTB4R2 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.